9:30 am Registration & Networking

10:00 am Understanding the Unique Biology of NK Cells Vs T Cells to Expand Your Knowledge Base on the Innate and Adaptive Immune System

• Mark Exley Founder, Senior Advisor & SAB Chair, MiNK Therapeutics

11:00 am Highlighting the Main Differences Between Engineered NK Cell Therapies and NK Cell Engager Therapies to Find the Best Tactical Insights to Take Back to Your Teams

• Wei Li Chief Scientific Officer, Cytovia Therapeutics

12:00 pm Lunch & Networking

1:00 pm Evaluating the Unique Use and Impact of NK Cells in Blood Cancers and Solid Tumors

• Erika von Euw Vice President of Discovery & Translational Research, Deverra Therapeutics

2:00 pm Autologous Vs Allogenic NK Cell Therapies – Which Has the Greatest Impact?

• Anna-Karin Maltais Chief Scientific Officer, XNK Therapeutics

3:00 pm Afternoon Break & Networking

3:30 pm Reviewing Different Genetic Engineering Techniques for NK Cells

• Sheila Lopez Acevedo Senior Scientist - Process Development, CytoImmune Therapeutics

4:30 pm Close of Preconference Day